Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
2.64% $3.11
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 155.99 mill |
EPS: | -1.330 |
P/E: | -2.34 |
Earnings Date: | Mar 19, 2024 |
SharesOutstanding: | 50.16 mill |
Avg Daily Volume: | 0.0794 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Strong Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.34 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.40x |
Company: PE -2.34 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.931 (-129.92%) $-4.04 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 2.86 - 3.28 ( +/- 6.87%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-21 | Mckinley Kate | Buy | 323 500 | Stock Option (Right to Buy) |
2024-03-21 | Hashim Mir | Buy | 323 500 | Stock Option (Right to Buy) |
2024-03-21 | Groen Eric | Buy | 323 500 | Stock Option (Right to Buy) |
2024-03-21 | Imran Talat | Buy | 1 085 000 | Stock Option (Right to Buy) |
2024-03-21 | Sanford Svai S | Buy | 323 500 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
19.27 |
Last 99 transactions |
Buy: 12 150 348 | Sell: 8 157 844 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.11 (2.64% ) |
Volume | 0.128 mill |
Avg. Vol. | 0.0794 mill |
% of Avg. Vol | 161.37 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.